Psychiatric Genetics & Genomics: From Variant Discovery to Clinical Practice
Over two decades, psychiatric research has evolved from twin-based family risk estimation to high-throughput single-cell multi-omics and actionable pharmacogenomics. Explore the evidence base, missing heritability gap, clinical utility, and ethical frameworks governing modern genomic psychiatry.
1. Genetic Architecture & The Heritability Gap
This section illustrates the concept of heritability across major psychiatric conditions and explores the fundamental gap between classical twin study estimates and molecular array SNP-based heritability ($h^2_{SNP}$). Understanding this missing heritability is critical to evaluating the limits of current predictive genomic testing.
Heritability Comparison: Twin vs. SNP Array
Interactive ChartClick on any bar or disorder button below to inspect the etiology of the variance gap.
Schizophrenia (SCZ)
Etiological Interpretation of Gap
Highly polygenic architecture. The massive missing heritability gap (~52%) is driven by rare structural variants (CNVs), highly penetrant un-genotyped rare SNPs, and gene-environment interaction effects not captured by standard common GWAS arrays.
2. Pleiotropy, Cross-Disorder Overlap & Consortia Discovery
Modern genomics demonstrates that biological reality does not align strictly with DSM-5 diagnostic categories. Genetic variants display extensive pleiotropy. Explore cross-disorder genetic correlations ($r_g$) and key functional discoveries from PsychENCODE Phase II, C4 complement biology, ENIGMA, and the UCLA DGC.
Common Variant Genetic Correlation ($r_g$) Matrix
70% of genetic signal in SCZ is shared with BPD. High shared polygenic liability.
1 Million Genomes & 5 Underlying Factors
Analyzing 14 psychiatric disorders across >1,000,000 individuals identified that overall risk converges on 5 core genomic factors comprising 238 shared genetic variants:
- Internalizing Factor: MDD, Anxiety, PTSD (Enriched in oligodendrocyte myelin maintenance genes).
- Compulsive Factor: Anorexia, OCD, Tourette's Disorder.
- Psychotic/Affective Factor: SCZ and BPD (Enriched in cortical excitatory neurons).
- Neurodevelopmental Factor: ASD, ADHD, Tourette's.
3. Polygenic Risk Scores (PRS) & The Risk Paradox
A Polygenic Risk Score aggregates hundreds of thousands of common variants into a single percentile score. While invaluable for research, international guidelines (ISPG) warn that **PRS is NOT ready for clinical diagnosis or embryo screening**. Interactively explore the paradox between high relative risk and low absolute risk below.
Schizophrenia PRS Risk Simulator
Even in the extreme Top 1% genetic risk category, 94% of individuals will NEVER develop schizophrenia. Predictive accuracy (AUC ~82%) falls below the 90% threshold required for diagnostic testing.
Visualizing 100 Individuals in this Risk Tier
4. Clinical Utility: Diagnostic Genetic Testing & Counseling
Diagnostic molecular testing is established as standard-of-care in neurodevelopmental disorders, but is reserved for specific "red flags" in adult-onset psychiatric conditions. Explore the clinical pathways and the role of Psychiatric Genetic Counseling (PGC).
Neurodevelopmental Pathway (ASD / ID / GDD)
Sequential testing provides a definitive molecular diagnosis in ~25% of cases, ending the diagnostic odyssey and guiding targeted medical monitoring.
First-Tier Testing
Chromosomal Microarray Analysis (CMA) for CNVs + Fragile X molecular testing.
Second-Tier Testing
If CMA is negative, perform Targeted Gene Panels or Whole-Exome Sequencing (WES).
Adult Psychiatry: Actionable Red Flags
Broad genetic testing is not recommended for routine adult psychiatry unless specific clinical red flags suggest underlying pathogenic CNVs.
- ✔ Clinical Red Flags: Dysmorphic facial features, congenital cardiac defects, early-onset dementia/movement disorders, or severe family history of neurodevelopmental delay.
- ✔ 22q11.2 Microdeletion: One of the strongest risk factors for adult schizophrenia (20-30x risk increase), adult ADHD, and seizures.
5. Pharmacogenomics (PGx): CPIC Guidelines Finder
Pharmacogenomics provides actionable clinical utility for treatment resistance or polypharmacy. Search and filter evidence-based CPIC prescribing recommendations across hepatic CYP enzymes and HLA immunologic markers.
6. Ancestral Diversity & Ethical Frameworks (ELSI)
Addressing the Euro-centric bias in genomic databases is both a scientific requirement and an ethical imperative. Explore global diversity initiatives and essential Ethical, Legal, and Social Implications (ELSI).
Major Ancestral Diversity Initiatives
Low-pass WGS across African, Native American, and admixed ancestries (40k SCZ, 40k BPD, 40k controls) led by UCLA to improve fine-mapping and global PRS validity.
Latin American Biobank for Severe Mental Illness targeting underrepresented Hispanic/Latin American cohorts from EMR data in the Paisa region.
Broad Institute, NY Genome Center, and UCLA sequencing Bipolar Disorder samples from Africa, Central/South America, and Asia.